Fujirebio

Fujirebio is global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.

PreCursor-M+

Qualitative detection of promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4 and hsa-miR124-2). Identify HPV positive women with high short-term progression to (pre)cancer.

(0)

HPV-Risk assay

Qualitative detection of 14 high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, 68) as well as putative HPV high risk type 67, with separate identification of HPV16 and 18...

(0)
Browse Products by Field

Fujirebio is global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.

Contact Fujirebio

Address: Technologiepark 6, 9052 Gent, Belgium

Website link